Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -102.59% is 19% below its 5-year average of -85.95%, near the high end of its 5-year range (-1570.44%–-45.26%).
As of the fiscal period ended Tuesday, June 30, 2026. 35.99% below its 12-month average of -75.44%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -102.59%.
RETURN ON INVESTED CAPITAL (ROIC)
-102.59%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-75.44%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-122.59%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-85.95%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-61.69%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
-35.99%
CURRENT VS 3Y AVG
+16.31%
CURRENT VS 5Y AVG
-19.36%
CURRENT VS 10Y AVG
-66.30%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-33.87%
median of 703 covered companies
CURRENT VS SECTOR MEDIAN
-202.89%
vs the sector median at left
Crescent Biopharma, Inc.
Market Cap
$522.80M
Return on Invested Capital (ROIC)
-102.59%
TTM Avg
-75.44%
3Y Avg
-122.59%
5Y Avg
-85.95%
Market Cap
$523.41M
Return on Invested Capital (ROIC)
-16.89%
TTM Avg
-20.74%
3Y Avg
-75.97%
5Y Avg
-65.59%
Market Cap
$520.22M
Return on Invested Capital (ROIC)
-19.47%
TTM Avg
-57.88%
3Y Avg
-52.57%
5Y Avg
-47.02%
Market Cap
$534.01M
Return on Invested Capital (ROIC)
-18.20%
TTM Avg
-95.31%
3Y Avg
-87.63%
5Y Avg
-71.60%
Market Cap
$536.22M
Return on Invested Capital (ROIC)
-78.31%
TTM Avg
-49.75%
3Y Avg
-41.99%
5Y Avg
-101.04%
Market Cap
$509.64M
Return on Invested Capital (ROIC)
-18.90%
TTM Avg
-35.16%
3Y Avg
-27.40%
5Y Avg
-20.34%
Market Cap
$539.40M
Return on Invested Capital (ROIC)
-0.81%
TTM Avg
-8.59%
3Y Avg
-110.96%
5Y Avg
-102.03%
Market Cap
$542.49M
Return on Invested Capital (ROIC)
-23.45%
TTM Avg
-110.35%
3Y Avg
-97.44%
5Y Avg
-86.64%
Market Cap
$503.89M
Return on Invested Capital (ROIC)
-34.79%
TTM Avg
-53.61%
3Y Avg
-51.25%
5Y Avg
-40.96%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Crescent Biopharma, Inc. (CBIO) | $522.80M | -102.59% | -75.44% | -122.59% | -85.95% |
| Monopar Therapeutics Inc. (MNPR)vs › | $523.41M | -16.89% | -20.74% | -75.97% | -65.59% |
| Altimmune, Inc. (ALT)vs › | $520.22M | -19.47% | -57.88% | -52.57% | -47.02% |
| Immix Biopharma, Inc. (IMMX)vs › | $534.01M | -18.20% | -95.31% | -87.63% | -71.60% |
| ProKidney Corp. (PROK)vs › | $536.22M | -78.31% | -49.75% | -41.99% | -101.04% |
| 908 Devices Inc. (MASS)vs › | $509.64M | -18.90% | -35.16% | -27.40% | -20.34% |
| Delcath Systems, Inc. (DCTH)vs › | $539.40M | -0.81% | -8.59% | -110.96% | -102.03% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $542.49M | -23.45% | -110.35% | -97.44% | -86.64% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $503.89M | -34.79% | -53.61% | -51.25% | -40.96% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $549.58M | -56.99% | -66.45% | -57.50% | -60.06% |
ROIC
-102.6%
ROE
-99.8%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -102.59% |
| 2026-03-31 | -88.21% |
| 2025-12-31 | -74.74% |
| 2025-09-30 | -66.40% |
| 2025-06-30 | -45.26% |
| 2025-03-31 | -1570.44% |
| 2024-12-31 | -939.06% |
| 2024-09-30 | -371.80% |
| 2024-06-30 | -203.75% |
| 2024-03-31 | -136.45% |
| 2023-12-31 | -102.06% |
| 2023-09-30 | -86.11% |
| 2023-06-30 | -71.06% |
| 2023-03-31 | -70.25% |
| 2022-12-31 | -110.42% |
| 2022-09-30 | -112.43% |
| 2022-06-30 | -111.89% |
| 2022-03-31 | -92.93% |
| 2021-12-31 | -76.88% |
| 2021-09-30 | -62.66% |
| 2021-06-30 | -50.80% |
| 2021-03-31 | -45.35% |
| 2020-12-31 | -39.50% |
| 2020-09-30 | -36.47% |
| 2020-06-30 | -34.75% |
| 2020-03-31 | -35.89% |
| 2019-12-31 | -39.10% |
| 2019-09-30 | -35.89% |
| 2019-06-30 | -32.71% |
| 2019-03-31 | -27.92% |
| 2018-12-31 | -24.99% |
| 2018-09-30 | -21.07% |
| 2018-06-30 | -18.26% |
| 2018-03-31 | -15.85% |
| 2017-12-31 | -28.18% |
| 2017-09-30 | -29.97% |
| 2017-06-30 | -27.94% |
| 2017-03-31 | -98.99% |
| 2016-12-31 | -88.51% |
| 2016-09-30 | -76.17% |
| 2016-06-30 | -63.87% |
| 2016-03-31 | -37.83% |
| 2015-12-31 | -31.40% |
| 2015-09-30 | -23.10% |
| 2015-06-30 | -19.59% |
| 2015-03-31 | -29.64% |
| 2014-12-31 | -21.93% |
| 2014-09-30 | -13.17% |
| 2014-06-30 | -7.20% |
| 2014-03-31 | -29.17% |
| 2013-12-31 | -352.88% |
| 2013-09-30 | -91.84% |
| 2013-06-30 | -15.91% |
